3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Dermatologic
2
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
10
Melanoma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Ovarian Neoplasms
3
Carcinoma, Merkel Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Interventions
pembrolizumab
14
Gemcitabine
8
Docetaxel
7
Nivolumab
6
durvalumab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
sargramostim
3
aldesleukin
3
Specimen Handling
3
Radiotherapy
3
Paclitaxel
3
Ipilimumab
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
venetoclax
2
temsirolimus
2
talazoparib
2
spartalizumab
2
olaparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
cabozantinib
2
budigalimab
2
avelumab
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
poly ICLC
×
Breast
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled